Find A Doctor Find A Service Make An Appointment Talk To A Doctor

McDowell Cancer Centerbanner
increase text size decrease text size printer friendly



> Centers & Services > Cancer Institute
 

Cancer Clinical Trials

Akron General's McDowell Cancer Institute provides patients with access to care quickly. We also offer the newest therapies, diagnostics and surgical techniques to help minimize side effects and improve outcomes. A research site with national clinical trials, we offer treatment options that may help extend and improve lives. The McDowell Cancer Institute is a member of six National Cancer Institute cooperative groups including: the American College of Radiology Imaging Network (ACRIN), American College of Surgeons Oncology Group (ACOSOG), Radiation Therapy Oncology Group (RTOG), Southwest Oncology Group (SWOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), and the Gynecologic Oncology Group (GOG). We also participate in pharmaceutical and in-house investigator-initiated studies.

Read more from Akron General:
What is a Clinical Trial?

View all Akron General Clinical Trials

For more information about options available through our cancer center clinical trials, please contact the McDowell Cancer Institute Research Department at 330-344-6348.

See below for active trials at the Akron General McDowell Cancer Institute

Additional resources for cancer clinical trials.

National Institutes of Health, National Cancer Institute
www.nci.nih.gov

American Cancer Society
www.cancer.org

 Date Updated: 23-JAN-2014
  
Blood
Bone Cancer
Bone Metastasis
Brain Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gynecology
Gynecology Cancer
Head and Neck
Head and Neck Cancer
Leukemia
Leukemia - Registry Study
Lung Cancer
Ovarian, Uterine Cancer
Pancreas Cancer
Prostate Cancer

Cancer Clinical Trials

Bladder Cancer

Title(s):
CTSU CALGB 90601. A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Blood

Title(s):
11026. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Bone Cancer

Title(s):
RTOG 0631. Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Bone Metastasis

Title(s):
SWOG 0702. A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
RTOG 1122. Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
RTOG 1205. Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NSABP B-43. A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Research 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU SCUSF 0806. Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo) Adjuvant Chemotherapy with Trastuzumab (Herceptin)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
SWOG 1007. A Phase II Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU E2108. A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
12010. Prediction of Margin Status During Lumpectomy - A Pilot Study

Investigator(s):
Daniel Guyton, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NSABP B-49. A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
RTOG 1119. Phase II Randomized Study Of Whole Brain Radiotherapy In Combination With Concurrent Lapatinib In Patients With Brain Metastasis From HER2-Positive Breast Cancer- A COLLABORATIVE STUDY OF RTOG AND KROG.

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
SWOG 1207. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
RTOG 1005. A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NSABP B-51/RTOG 1304. A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
SWOG 1202. A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (Al)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348.


Go to top

Breast Cancer

Title(s):
13049. Neoadjuvant Breast Registry - Symphony ™ Trial (NBRST) (pronounced "in breast")

Investigator(s):
Mary Murray, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU E1Z11. Treating Aromatase Inhibitor Musculoskeletal Symptoms related to Anastrozole in Female Patients With Stage I-III Breast Cancer --A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Cervical Cancer

Title(s):
RTOG/GOG 0724. Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Cervical Cancer

Title(s):
RTOG 1203. A Randomized Phase III Study Of Standard VS. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (Time-C)

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research


Go to top

Colon Cancer

Title(s):
CTSU CALGB 80702. A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Colon Cancer

Title(s):
13026. Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

Investigator(s):
Kevin Lowe, MD

Contact Information:
McDowell Cancer Research at 330-344-6348.


Go to top

Esophageal Cancer

Title(s):
SWOG 1201. A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gynecology

Title(s):
GOG 0273. Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gynecology Cancer

Title(s):
GOG 0235. A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck

Title(s):
CTSU E1311. A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
CTSU E1305. A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
RTOG 0920. A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
RTOG 1016. Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
RTOG 1216. Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Leukemia

Title(s):
CTSU E2906. Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Leukemia - Registry Study

Title(s):
11001. CA180-330 (SIMPLICITY) Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study

Investigator(s):
John Petrus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU CALGB 30610. Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
SWOG 0819. A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
RTOG 0937. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU E5508. Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
RTOG 1306. A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Ovarian, Uterine Cancer

Title(s):
GOG 0261. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Pancreas Cancer

Title(s):
RTOG 0848. A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Pancreas Cancer

Title(s):
SWOG 1115. Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy NCI Version Date: 7/17/12

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348.


Go to top

Pancreas Cancer

Title(s):
RTOG 1201. A Phase II Randomized Trial of High versus Standard Intensity Local or Systemic Therapy for Unresectable Pancreatic Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Pancreas Cancer

Title(s):
CTSU E2211. A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0534. A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0815. A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0526. A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
CTSU CALGB 70807. The Men's Easting and Living (MEAL)Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0622. A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer after Radical Prostatectomy.

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0924. Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
11043. EFC11785/PROSELICA Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen.

Investigator(s):
Esther Rehums, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 1115. Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top



Akron General Medical Center • 1 Akron General Avenue (Formerly 400 Wabash Avenue) • Akron, OH 44307 • 330-344-6000 • 1-800-221-4601    © 2014 Akron General Health System
Find Us on Facebook button


This website is certified by Health On the Net Foundation. Click to verify.

  This site complies with the HONcode standard for trustworthy health information: verify here.